- Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Defiance Daily Target 2X Long MRNA ETF(MRNX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MRNX
11/20/2026: MRNX (1-star) is currently NOT-A-BUY. Pass it for now.
The Defiance Daily Target 2X Long MRNA ETF (MRNX) provides leveraged synthetic exposure designed to deliver twice the daily price return of Moderna, Inc. through swap agreements. Its main strengths lie in offering efficient short-term tactical leverage and single-stock access without requiring a margin account. The fund serves as an active trading tool for expressing bullish momentum views on Moderna over single-session horizons. Primary risks include severe volatility decay, compounding erosion over multi-day periods, and extreme single-stock concentration. It is tailored strictly for experienced short-term traders who closely monitor their positions and market conditions.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | Leveraged single-stock ETFs are designed for short-term tactical trading rather than long-term growth investing. |
| Momentum investor | Strong fit while signal remains positive | Active momentum traders can utilize its 2x daily leverage to capitalize on short-term bullish breakouts in Moderna shares. |
| Value investor | Weak fit | The fund's daily reset mechanism and derivative overlays make it entirely unsuitable for traditional fundamental value strategies. |
| Dividend/Income investor | Weak fit | MRNX does not focus on dividend income and is designed exclusively for capital appreciation via short-term leverage. |
| Low-risk investor | Weak fit | High volatility, compounding risk, and single-stock concentration make this product inappropriate for conservative capital preservation. |
Investor Profile
Ideal Investor Profile
Active tactical traders, day traders, and sophisticated short-term speculators seeking leveraged bullish exposure to Moderna without margin accounts.
Suitability
Best suited exclusively for intraday or very short-term tactical holding periods; entirely unsuitable for buy-and-hold or long-term investors.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | Magnified daily movements and compounding effects can lead to rapid capital erosion during choppy market conditions. |
| Market risk | High | The fund's value is directly vulnerable to adverse price drops in Moderna shares. |
| Concentration | High | The portfolio has 100% synthetic concentration tied to a single underlying corporate security (Moderna). |
| Tracking/expense | Medium / high | Higher expense ratios and compounding divergence over holding periods longer than one day impact net returns. |
| Liquidity | Medium | Trading volumes can fluctuate based on news cycles surrounding the underlying stock, impacting execution costs. |
| Business/sector quality | High | The fund's viability depends entirely on the operational performance and clinical pipeline success of Moderna. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
MRNX exhibits high historical volatility driven by daily 2x leverage compounding and the inherent price swings of Moderna stock.
Market Risk
Carries extreme single-issuer risk, meaning negative news or sharp downward corrections in Moderna directly inflict magnified losses.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Single stock | Moderna Inc. (MRNA) — seeks 2x daily return | 100 | Provides leveraged synthetic exposure aiming to double the daily price movements of Moderna, Inc. shares. |
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type ETF | Historic Profit 16.61% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | ETF Returns Performance |

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

